Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial

JAMA

Volumn 300, Issue 8, 2008, Pages 924-932

  Feig, Daniel I ^a   Soletsky, Beth ^a   Johnson, Richard J ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; PLACEBO;

ADOLESCENT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERURICEMIA; LIVER INJURY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEVENS JOHNSON SYNDROME; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNITED STATES; URIC ACID BLOOD LEVEL; VOMITING;

EID: 50449095362     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.8.924     Document Type: Article

References (49)

1. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275(9):457-464.
2. Williams J. The total nonprotein nitrogen constituents of the blood in arterial hypertension. Arch Intern Med. 1922;27:748-754.
3. Mohamed FA. On chronic Bright's disease, and its essential symptoms. Lancet. 1879;1:399-401.
4. Haig A. Onuric acid and arterial tension. BMJ. 1889;1:288-291.
5. Davis N. The cardiovascular and renal relations and manifestations of gout. JAMA. 1897;29:267-262.
6. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93(6):817-821.
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
8. Vaccarino V, Krumholz HM. Risk factors for cardiovascular disease: one down, many more to evaluate. Ann Intern Med. 1999;131(1):62-63.
9. Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45(1):28-33.
10. Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension. 2005;45(1):34-38.
11. Selby JV, Friedman GD, Quesenberry CP Jr. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol. 1990;131(6):1017-1027.
12. Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the Atherosclerosis Risk in Communities study. Hypertension. 2006;48(6):1037-1042.
13. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48(6):1031-1036.
14. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49(2):298-303.
15. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42(3):247-252.
16. Johnson RJ, Rideout BA. Uric acid and diet-insights into the epidemic of cardiovascular disease. N Engl J Med. 2004;350(11):1071-1073.
17. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101-1106.
18. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991-F997.
19. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol. 2005;16(7):1909-1919.
20. Sánchez-Lozada LG, Tapia E, Lopez-Molina R, et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol. 2007;292(4):F1238-F1244.
21. Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract. 2005;59(11):1276-1282.
22. Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006;17(5):1466-1471.
23. Gruskin AB. The adolescent with essential hypertension. Am J Kidney Dis. 1985;6(2):86-90.
24. Saito I, Saruta T, Kondo K, et al. Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc. 1978;26(6):241-247.
25. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105(22):2619-2624.
26. Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94(7):932-935.
27. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106(2):221-226.
28. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics. 2004;114(2 suppl 4th report):555-576.
29. Isaacman DJ, Reynolds EA. Effect of a research nurse on patient enrollment in a clinical study. Pediatr Emerg Care. 1996;12(5):340-342.
30. Soergel M, Kirschstein M, Busch C, et al. Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr. 1997;130(2):178-184.
31. Wang GT, Chung CC, Holzman TF, Krafft GA. A continuous fluorescence assay of renin activity. Anal Biochem. 1993;210(2):351-359.
32. Lasater M. The view within: the emerging technology of thoracic electrical bioimpedance. Crit Care Nurs Q. 1998;21(3):97-101.
33. Ventura HO, Pranulis MF, Young C, Smart FW. Impedance cardiography: a bridge between research and clinical practice in the treatment of heart failure. Congest Heart Fail. 2000;6(2):94-102.
34. Greenberg BH, Hermann DD, Pranulis MF, Lazio L, Cloutier D. Reproducibility of impedance cardiography hemodynamic measures in clinically stable heart failure patients. Congest Heart Fail. 2000;6(2):74-80.
35. Pranulis MF. Impedance cardiography (ICG) noninvasive hemodynamic monitoring provides an opportunity to deliver cost effective, quality care for patients with cardiovascular disorders. J Cardiovasc Manag. 2000;11(3):13-17.
36. Smith RD, Levy P, Ferrario CM. Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects. Hypertension. 2006;47(4):771-777.
37. Pianosi PT. Measurement of exercise cardiac output by thoracic impedance in healthy children. Eur J Appl Physiol. 2004;92(4-5):425-430.
38. Ferreira AP, Oliveira CER, Franca NM. Metabolic syndrome and risk factors for cardiovascular disease in obese children: the relationship with insulin resistance (HOMA-IR). J Pediatr. 2007;83(1):21-26.
39. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008;10(2):130-139.
40. Crom WR, Webster SL, Bobo L, Teresi ME, Relling MV, Evans WE. Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clin Pharmacol Ther. 1987;41(6):645-650.
41. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270(6):713-724.
42. Simonetti GD, Rizzi M, Donadini R, Bianchetti MG. Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. J Hypertens. 2007;25(12):2370-2376.
43. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358(9290):1305-1315.
44. Toma I, Kang J, Meer E, Pet-Peterdi J. Uric acid triggers renin release via a macula densa-dependent pathway. Presented at: American Society of Nephrology Annual Meeting; November 2007; San Francisco, CA. F-P0240.
45. Watanabe S, Kang DH, Feng L, et al. Uric acid hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355-360.
46. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113(3 pt 1):475-482.
47. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508-2516.
48. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287-1293.
49. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584-C596.